Table 1.
Patient characteristics and mortality
| GCS ≥ 13 | GCS <13 | |
|---|---|---|
| Gender (M/F; n) | 12/11 | 21/10 |
| Age (years; mean ± SD) | 69 ± 13 | 72 ± 10 |
| APACHE II score (mean ± SD) | 17 ± 4 * | 25 ± 7 |
| Baseline SOFA score (mean ± SD) | 8 ± 2 * | 10 ± 3 |
| Baseline S100B (μg/L; mean ± SEM) | 0.70 ± 0.08° | 0.96 ± 0.15 |
| ICU mortality (n; %)† | ||
| DrotAA | 6 (67) | 10 (67) |
| No DrotAA | 7 (50) | 9 (56) |
| Hospital mortality (n; %) | ||
| DrotAA | 6 (67) | 13 (86) |
| No DrotAA | 10 (71) | 12 (75) |
* P < 0.05, °P = 0.05 as compared to patients with GCS <13
† number and percentage of DrotAA-treated or -untreated patients who died
APACHE: Acute Physiology and Chronic Health Evaluation; DrotAA: drotrecogin alfa (activated); F: female; ICU: intensive care unit; M: male; SOFA: Sequential Organ Failure Assessment